Portman Square Capital’s BridgeBio Pharma BBIO Stock Holding History

Portman Square Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.47M	Hold	60,000	–	–	0.21%	67
2026 Q1	$4.46M	Sell	60,000 -125,900	-68%	-$9.13M	0.17%	79
2025 Q4	$14.2M	Sell	185,900 -20,000	-10%	-$1.31M	0.63%	41
2025 Q3	$10.7M	Sell	205,900 -289,600	-58%	-$14.1M	0.47%	47
2025 Q2	$21.4M	Buy	495,500 +190,000	+62%	+$6.91M	0.63%	34
2025 Q1	$10.6M	Buy	305,500 +28,300	+10%	+$954K	0.28%	98
2024 Q4	$7.61M	Hold	277,200	–	–	0.27%	86
2024 Q3	$7.06M	Buy	277,200 +38,000	+16%	+$998K	0.26%	114
2024 Q2	$6.06M	Sell	239,200 -457,400	-66%	-$12.5M	0.21%	135
2024 Q1	$21.5M	Sell	696,600 -107,200	-13%	-$3.65M	0.6%	51
2023 Q4	$32.4M	Sell	803,800 -80,000	-9%	-$2.4M	0.74%	29
2023 Q3	$23.3M	Buy	+883,800	New	+$25.1M	0.57%	43

Other funds holding BBIO

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

MMA

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Portman Square Capital's BBIO Position: Q4 2025 in Review

Portman Square Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 117,826 shares — an estimated $7.73M sold.

Portman Square Capital first reported a position in BBIO in Q3 2023 and held it in 9 quarters. The position peaked at $6.29M in Q2 2025. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Portman Square Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Portman Square Capital sold 117,826 BridgeBio Pharma shares in Q4 2025, an estimated $7.73M.
Portman Square Capital first reported a position in BridgeBio Pharma in Q3 2023 and held it in 9 quarters.
Portman Square Capital's BridgeBio Pharma position peaked at $6.29M in Q2 2025.
432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Portman Square Capital's 13F filing for Q4 2025, filed 23 Jan 2026.